Plain-English translation of NCT05744687 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new drug called SPH4336 combined with letrozole, a hormone therapy medicine, for women with advanced breast cancer that cannot be surgically removed. About 374 women will be randomly assigned to receive either SPH4336 plus letrozole or a placebo (a dummy pill) plus letrozole, to see if the medication helps slow cancer growth and is safe to take.
Current hormone therapy treatments don't work well enough for all patients with this type of advanced breast cancer. Researchers believe this medication might work better when combined with standard hormone therapy to help more patients live longer and healthier lives.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will take either SPH4336 tablets or a placebo tablet by mouth every day, along with letrozole tablets, for as long as the treatment is helping and you are tolerating it well. You will have regular clinic visits for blood tests, physical exams, and imaging scans to monitor how you are responding and to check for side effects. The study team will keep track of your health closely throughout your participation.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China